US FDA approve Merck’s Bravecto tablet for dogs to treat fleas and ticks

Posted on Updated on

The US Food and Drug Administration has approved Merck Animal Health‘s Bravecto (fluralaner) chewable tablets for dogs (112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg).  Bravecto is the first and only treatment that has been shown to quickly and effectively kill fleas and multiple tick species for 12 weeks in a single dose. It is also is effective for eight weeks against Amblyomma americanum ticks.

“Bravecto is a breakthrough innovation that offers pet owners and veterinarians something that no other product does the longest-lasting oral flea and tick prevention currently available,” said KJ Varma, senior vice president, research and development, Merck Animal Health. “The approval of Bravecto is truly a reflection of our 70-year history of innovation, research and commitment to helping shape the future of animal health, as well as our dedication to bringing novel products to market that meet the evolving needs of pet owners, customers and the industry.”

Bravecto comes in a convenient, single-dose chewable tablet and offers, Immediate and persistent flea (Ctenocephalides felis) killing activity for 12 weeks; Immediate and persistent tick killing activity for 12 weeks (Ixodes scapularis black-legged tick, Dermacentor variabilis;.American dog tick, and Rhipicephalus sanguineus brown dog tick); Immediate and persistent tick killing activity for 8 weeks (Amblyomma americanum lone star tick);

“Effective flea and tick control used regularly is a crucial part of a pet’s overall health regimen,” said Kathleen Heaney, D.V.M., director of technical services, companion animals, Merck Animal Health.  “Bravecto offers pet owners an easy-to-administer chewable product that is fast-acting and lasts nearly three times longer than conventional, monthly flea and tick products.”

The active substance of Bravecto, fluralaner, a new ectoparasiticide belonging to the isoxazoline group, is systemically active against fleas and ticks. Bravecto is presented as a flavored chew that dogs accept readily. The product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD) as a direct result of eliminating flea infestations. The most common side effects are mild and transient gastrointestinal effects.

Bravecto is available only through licensed veterinarians and it is effective for eight weeks against Amblyomma americanum ticks.

Source: PharmaBiz


Let us know what you think!

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s